ProPhase Labs Company Top Insiders
| PRPH Stock | USD 0.09 0.01 7.93% |
ProPhase Labs employs about 96 people. The company is managed by 13 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 7.38 employees per reported executive. Management-performance analysis for ProPhase Labs gives investors another way to evaluate how leadership is influencing execution, capital allocation, and operating discipline. Used properly, management analysis helps separate durable execution from results that may only reflect a supportive market cycle.
| Ted Karkus Chairman Chairman and CEO |
ProPhase | Build portfolio with ProPhase Stock |
Management Team Effectiveness
The company has return on total asset (ROA) of -23.5 % suggesting that asset deployment is not yet covering its cost of capital. This trails well behind sector averages. Similarly, it shows a return on stockholder's equity (ROE) of -220.34 %, meaning that equity holders received a negative return on their investment.As of last month (February 2026), Net Income Applicable To Common Shares is projected to grow to approximately 7.6 M, although Common Stock Shares Outstanding is expected to fall to under 2.1 M.
Stock Institutional Investors
ProPhase Labs has 3.31% institutional ownership and 5.05% insider stake. Annual revenue is about 6.77 Million. This mix shapes how the stock trades around earnings. Shares outstanding are near 4.7 M. Whether the institutional base is growing or shrinking quarter over quarter matters more than the current snapshot.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 9.2 K | Jpmorgan Chase & Co | 2025-09-30 | 3.5 K | Wells Fargo & Co | 2025-09-30 | 1.5 K | Bank Of America Corp | 2025-09-30 | 1.1 K | Corecap Advisors, Llc | 2025-12-31 | 720 | Tower Research Capital Llc | 2025-12-31 | 163 | Sbi Securities Co Ltd | 2025-12-31 | 50.0 | Susquehanna International Group, Llp | 2025-12-31 | 0.0 | Bkb Wealth Advisors, Llc | 2025-12-31 | 0.0 | Vanguard Group Inc | 2025-12-31 | 53.2 K | State Street Corp | 2025-09-30 | 44.7 K |
Insider Trading Activities
Insider activity around ProPhase Labs matters because officers and directors often act on business changes before the market catches up. Most U.S. insider trades appear in Form 4 filings. The value comes from reading the sequence, not one filing in isolation.
Outstanding Bonds
ProPhase Labs may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US74348YAV39 Corp BondUS74348YAV39 | View | |
| US74348YDX67 Corp BondUS74348YDX67 | View | |
| PROSPECT CAP P Corp BondUS74348YEA55 | View | |
| US74348TAV44 Corp BondUS74348TAV44 | View | |
| PSEC 3437 15 OCT 28 Corp BondUS74348TAW27 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Shares in Circulation | First Issued 1996-12-31 | Previous Quarter 4.2 M | Current Value 4.2 M | Average Shares Outstanding 2 M | Quarterly Volatility 3.3 M |
Macro event markers
Holders Distribution
Institutional investors in ProPhase Labs typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. The better interpretation comes from watching concentration, turnover, and changes in holder behavior instead of assuming institutional ownership is automatically bullish.
Market Cap and Value
Workforce Comparison
ProPhase Labs places third for number of employees among direct rivals. The total workforce of Health Care industry is at this time estimated at about 1,138. ProPhase Labs holds roughly 96.0 in number of employees claiming about 8% of equities under Health Care sector.
Insider Trading History
The buy-sell ratio in ProPhase Labs' insider history separates pay-related activity from trades based on conviction. Investors focus on trades outside normal pay timelines, as those are more likely to reflect genuine conviction.
Notable Stakeholders
Reviewing the stakeholders around ProPhase Labs can help investors understand which people or institutions may influence direction, governance, and strategic pressure. The practical value is that investors can see where interests align, where they conflict, and how that tension could influence execution.
| Ted Karkus | Chairman and CEO | Profile | |
| Jason Karkus | President Diagnostics | Profile | |
| Alice Lioi | EVP BioPharma | Profile | |
| Billy White | Consultant | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Kevin Quinn | Chief Genomics | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Kamal Obbad | Senior Genomics | Profile | |
| Monica Brady | Principal Financial Officer & Principal Accounting Officer | Profile | |
| Jed Latkin | Chief Department | Profile |
Management Information & Data Sources
ProPhase Labs is a micro-cap company in Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Leadership review helps frame whether management actions match reported operating results. CEO is Ted Karkus with 96 employees and 13 reported executives.
Reported values for ProPhase Labs are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Refresh times depend on source availability. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing ProPhase Labs can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. The business is commonly classified in the Healthcare sector and the Drug Manufacturers—Specialty & Generic industry.
ProPhase Labs Manpower Efficiency
Return on ProPhase Labs Manpower
| Revenue Per Employee | 70.5K | |
| Revenue Per Executive | 520.8K | |
| Net Loss Per Employee | 515.9K | |
| Net Loss Per Executive | 3.8M |
Popular Tools for ProPhase Stock analysis
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |